1186606-90-5Relevant articles and documents
Pyrazolopyridine inhibitors of B-RafV600E. Part 1: The development of selective, orally bioavailable, and efficacious inhibitors
Wenglowsky, Steve,Ren, Li,Ahrendt, Kateri A.,Laird, Ellen R.,Aliagas, Ignacio,Alicke, Bruno,Buckmelter, Alex J.,Choo, Edna F.,Dinkel, Victoria,Feng, Bainian,Gloor, Susan L.,Gould, Stephen E.,Gross, Stefan,Gunzner-Toste, Janet,Hansen, Joshua D.,Hatzivassiliou, Georgia,Liu, Bonnie,Malesky, Kim,Mathieu, Simon,Newhouse, Brad,Raddatz, Nicholas J.,Ran, Yingqing,Rana, Sumeet,Randolph, Nikole,Risom, Tyler,Rudolph, Joachim,Savage, Scott,Selby, Leann T.,Shrag, Michael,Song, Kyung,Sturgis, Hillary L.,Voegtli, Walter C.,Wen, Zhaoyang,Willis, Brandon S.,Woessner, Richard D.,Wu, Wen-I,Young, Wendy B.,Grina, Jonas
scheme or table, p. 342 - 347 (2011/07/09)
The V600E mutation of B-Raf kinase results in constitutive activation of the MAPK signaling pathway and is present in approximately 7% of all cancers. Using structure-based design, a novel series of pyrazolopyridine inhibitors of B-RafV600E was
